Search the web
Welcome, Guest
[Sign Out, My Account]

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
THRX > SEC Filings for THRX > Form 8-K on 9-Dec-2013All Recent SEC Filings

Show all filings for THERAVANCE INC



Other Events

Item 8.01 Other Events.

On December 9, 2013, GlaxoSmithKline plc (GSK) and Theravance, Inc. announced the launch of RelvarŽ ElliptaŽ, the first once-daily ICS/LABA medication for asthma in Japan. Relvar Ellipta is indicated for bronchial asthma (in the case where concurrent use of inhaled corticosteroid (ICS) and long-acting inhaled beta2 agonist (LABA) is required). The launch follows the recent approval by the Japanese Ministry of Health, Labor and Welfare (MHLW) on September 20, 2013. Relvar is a combination of the inhaled corticosteroid (ICS), fluticasone furoate "FF", and the long-acting beta2 agonist (LABA), vilanterol "VI" (FF/VI). Two strengths of FF/VI have been approved for the treatment of asthma, 100/25 mcg and 200/25 mcg, and will be administered once-daily using the Ellipta, a new dry powder inhaler (DPI). Relvar Ellipta has been developed under the collaboration agreement between Glaxo Group Limited and Theravance, Inc. Theravance, Inc. is obligated to make a milestone payment of $10 million (USD) to GSK following the launch of Relvar Ellipta in Japan.

  Add THRX to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for THRX - All Recent SEC Filings
Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.